Nicotinic Agonist Effects on BMI and Neuronal Response
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
Details and patient eligibility
About
Obesity is a serious and growing health problem in the United States. Obesity is associated with health problems such as type-2 diabetes and cardiovascular disease, leading to decreased quality of life and increased mortality. Given the health and quality-of-life effects of obesity, developing effective treatments clearly is an important goal.
This study plans to learn more about the effects of an investigational new drug (DMXB-A (3-(2,4-dimethoxybenzylidene anabaseine)) and its effects on obesity. The study drug has similar effects to nicotine. Since nicotine has been found to affect appetite, the investigators are interested in studying effects of the study drug, which has some similarities to nicotine, on how your brain responds to such things as pictures of food. The study drug has not been approved by the Food and Drug Administration (FDA), and is considered experimental.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Overweight/obese (BMI > 27)
- Between 21-65 years old
Exclusion criteria
- Known cardiovascular disease (e.g., coronary artery disease, uncontrolled hypertension
- Women capable of conception (must be post-menopausal, surgically sterilized, or have adhered to an anti-contraception birth control regimen for at least 1 year)
- Nicotine use
- Significant endocrine/metabolic disease
- Kidney disease
- Neurological illness
- Liver disease
- Medication use affecting appetite and/or metabolism
- MRI-specific exclusion criteria (e.g., claustrophobia, metal in the body)
Trial design
Primary purpose
Allocation
Interventional model
Masking
61 participants in 2 patient groups, including a placebo group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal